362 related articles for article (PubMed ID: 29626315)
1. New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer's Disease.
Zhong KL; Chen F; Hong H; Ke X; Lv YG; Tang SS; Zhu YB
Metab Brain Dis; 2018 Aug; 33(4):1009-1018. PubMed ID: 29626315
[TBL] [Abstract][Full Text] [Related]
2. Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease.
Alagiakrishnan K; Sankaralingam S; Ghosh M; Mereu L; Senior P
Discov Med; 2013 Dec; 16(90):277-86. PubMed ID: 24333407
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis.
Cao B; Rosenblat JD; Brietzke E; Park C; Lee Y; Musial N; Pan Z; Mansur RB; McIntyre RS
Diabetes Obes Metab; 2018 Oct; 20(10):2467-2471. PubMed ID: 29790638
[TBL] [Abstract][Full Text] [Related]
4. New insights toward molecular and nanotechnological approaches to antidiabetic agents for Alzheimer's disease.
Pradhan SP; Sahu PK; Behera A
Mol Cell Biochem; 2023 Dec; 478(12):2739-2762. PubMed ID: 36949264
[TBL] [Abstract][Full Text] [Related]
5. Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus.
Pelle MC; Zaffina I; Giofrè F; Pujia R; Arturi F
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511061
[TBL] [Abstract][Full Text] [Related]
6. Glibenclamide mitigates cognitive impairment and hippocampal neuroinflammation in rats with type 2 diabetes and sporadic Alzheimer-like disease.
Esmaeili MH; Enayati M; Khabbaz Abkenar F; Ebrahimian F; Salari AA
Behav Brain Res; 2020 Feb; 379():112359. PubMed ID: 31733313
[TBL] [Abstract][Full Text] [Related]
7. Antidiabetic Polypill Improves Central Pathology and Cognitive Impairment in a Mixed Model of Alzheimer's Disease and Type 2 Diabetes.
Infante-Garcia C; Ramos-Rodriguez JJ; Hierro-Bujalance C; Ortegon E; Pickett E; Jackson R; Hernandez-Pacho F; Spires-Jones T; Garcia-Alloza M
Mol Neurobiol; 2018 Jul; 55(7):6130-6144. PubMed ID: 29224179
[TBL] [Abstract][Full Text] [Related]
8. Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: a systematic review.
Avgerinos KI; Kalaitzidis G; Malli A; Kalaitzoglou D; Myserlis PG; Lioutas VA
J Neurol; 2018 Jul; 265(7):1497-1510. PubMed ID: 29392460
[TBL] [Abstract][Full Text] [Related]
9. Antidiabetic Drugs in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review.
Muñoz-Jiménez M; Zaarkti A; García-Arnés JA; García-Casares N
Dement Geriatr Cogn Disord; 2020; 49(5):423-434. PubMed ID: 33080602
[TBL] [Abstract][Full Text] [Related]
10. Diabetes drugs and neurological disorders: new views and therapeutic possibilities.
Patrone C; Eriksson O; Lindholm D
Lancet Diabetes Endocrinol; 2014 Mar; 2(3):256-62. PubMed ID: 24622756
[TBL] [Abstract][Full Text] [Related]
11. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia.
Claxton A; Baker LD; Hanson A; Trittschuh EH; Cholerton B; Morgan A; Callaghan M; Arbuckle M; Behl C; Craft S
J Alzheimers Dis; 2015; 44(3):897-906. PubMed ID: 25374101
[TBL] [Abstract][Full Text] [Related]
12. Protection against Brain Atrophy by Anti-dementia Medication in Mild Cognitive Impairment and Alzheimer's Disease: Meta-Analysis of Longitudinal Randomized Placebo-Controlled Trials.
Kishi T; Matsunaga S; Oya K; Ikuta T; Iwata N
Int J Neuropsychopharmacol; 2015 Jun; 18(12):. PubMed ID: 26091818
[TBL] [Abstract][Full Text] [Related]
13. Antidiabetic Drugs in the Treatment of Alzheimer's Disease.
Michailidis M; Tata DA; Moraitou D; Kavvadas D; Karachrysafi S; Papamitsou T; Vareltzis P; Papaliagkas V
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563031
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease.
Popp J; Arlt S
Curr Opin Psychiatry; 2011 Nov; 24(6):556-61. PubMed ID: 21934621
[TBL] [Abstract][Full Text] [Related]
15. [The role of antidiabetic drugs in the treatment of Alzheimer's disease: systematic review].
Ishmuratova AN; Abramov MA; Kuznetsov KO; Ivanyuta MV; Shakirova ZF; Kitapova AI; Usmonov MD; Chernousova LM; Valeeva LI; Kuznetsova AY; Baislamov AS; Shaihetdinova AR; Mirgaliev AA; Orozberdiev ST; Yakupova KI
Probl Endokrinol (Mosk); 2023 Nov; 69(5):73-83. PubMed ID: 37968954
[TBL] [Abstract][Full Text] [Related]
16. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2.
Plastino M; Fava A; Pirritano D; Cotronei P; Sacco N; Sperlì T; Spanò A; Gallo D; Mungari P; Consoli D; Bosco D
J Neurol Sci; 2010 Jan; 288(1-2):112-6. PubMed ID: 19836029
[TBL] [Abstract][Full Text] [Related]
17. Is Alzheimer's disease a type 3 diabetes? A review.
Janoutová J; Machaczka O; Zatloukalová A; Janout V
Cent Eur J Public Health; 2022 Sep; 30(3):139-143. PubMed ID: 36239360
[TBL] [Abstract][Full Text] [Related]
18. Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones.
Cardoso S; Moreira PI
Int Rev Neurobiol; 2020; 155():37-64. PubMed ID: 32854858
[TBL] [Abstract][Full Text] [Related]
19. Antidiabetic Drugs in Alzheimer's Disease: Mechanisms of Action and Future Perspectives.
Femminella GD; Bencivenga L; Petraglia L; Visaggi L; Gioia L; Grieco FV; de Lucia C; Komici K; Corbi G; Edison P; Rengo G; Ferrara N
J Diabetes Res; 2017; 2017():7420796. PubMed ID: 28656154
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer's disease and amnestic mild cognitive impairment: a systematic review and meta-analysis.
Liu J; Wang LN; Jia JP
Drugs Aging; 2015 Jan; 32(1):57-65. PubMed ID: 25504005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
